Core Viewpoint - The article discusses the strategic leadership of Geoff Martha at Medtronic, focusing on his approach to innovation, crisis management, and the restructuring of the company's product portfolio to emphasize high-growth areas in the medical technology sector [2][5][21]. Strategic Layout - Medtronic is shifting its focus towards high-growth sectors by divesting from patient monitoring and respiratory intervention businesses, and plans to spin off its diabetes segment, concentrating resources on neuromodulation, cardiac ablation, and robotics [5][12]. Crisis Response - During the COVID-19 pandemic, Martha made a high-risk decision to open-source ventilator designs, which alleviated equipment shortages globally and earned Medtronic the Fortune "Change the World" award, reflecting a commitment to corporate responsibility [7][8]. Financial Performance - In fiscal year 2025, Martha's total compensation was $23.3 million, a 16% increase year-over-year, with 80%-90% tied to long-term incentives. Medtronic's revenue grew by 3.6% to $33.5 billion, and profit increased by 27% [8][9][11]. Innovation Focus - Key projects under Martha's leadership include the Symplicity SpyralRDN system for hypertension, adaptive deep brain stimulation for Parkinson's, and AI-assisted endoscopy for early cancer detection, indicating a strong commitment to advancing medical technology [12][21]. Talent Strategy - Martha promotes a decentralized R&D model to foster innovation, allowing business units greater autonomy and accelerating product development. This approach, along with equity incentives and diverse networks, aims to create a culture conducive to continuous innovation [14][21]. Cross-Industry Innovation - Medtronic is applying its heart monitoring technology to wildlife conservation efforts, showcasing the company's mission to extend its technological capabilities beyond traditional healthcare applications [18][21].